Published in Physiology (Bethesda) on November 01, 2013
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension (2014) 0.95
Myocardial Infarction Superimposed on Aging: MMP-9 Deletion Promotes M2 Macrophage Polarization. J Gerontol A Biol Sci Med Sci (2015) 0.87
Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl (2014) 0.86
Autodigestion: Proteolytic Degradation and Multiple Organ Failure in Shock. Shock (2016) 0.85
Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. Int J Obes (Lond) (2015) 0.84
Systemic inflammation on postnatal days 21 and 28 and indicators of brain dysfunction 2years later among children born before the 28th week of gestation. Early Hum Dev (2015) 0.83
Morin Attenuates Ovalbumin-Induced Airway Inflammation by Modulating Oxidative Stress-Responsive MAPK Signaling. Oxid Med Cell Longev (2015) 0.78
The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction. IUBMB Life (2015) 0.78
Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults. Diabetol Metab Syndr (2015) 0.78
Wnt10b Gain-of-Function Improves Cardiac Repair by Arteriole Formation and Attenuation of Fibrosis. Circ Res (2015) 0.78
Thrombospondins in the transition from myocardial infarction to heart failure. J Mol Cell Cardiol (2015) 0.77
System-based proteomic and metabonomic analysis of the Df(16)A(+/-) mouse identifies potential miR-185 targets and molecular pathway alterations. Mol Psychiatry (2016) 0.77
Matrix Metalloproteinase 9 Exerts Antiviral Activity against Respiratory Syncytial Virus. PLoS One (2015) 0.77
Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.77
Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition. Cardiology (2015) 0.77
Matrix metalloproteinase-9-dependent mechanisms of reduced contractility and increased stiffness in the aging heart. Proteomics Clin Appl (2015) 0.76
MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.76
Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol (2016) 0.76
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol (2014) 0.76
Practical alternatives to chronic caloric restriction for optimizing vascular function with ageing. J Physiol (2016) 0.75
Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? Expert Rev Cardiovasc Ther (2016) 0.75
Cyp26 Enzymes Facilitate Second Heart Field Progenitor Addition and Maintenance of Ventricular Integrity. PLoS Biol (2016) 0.75
CO-releasing molecules CORM2 attenuates angiotensin II-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression. Redox Biol (2017) 0.75
Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9. Exp Ther Med (2014) 0.75
Physiology in perspective: cell migration and the regenerative process. Physiology (Bethesda) (2013) 0.75
Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators Inflamm (2017) 0.75
MCP-1 downregulates MMP-9 export via vesicular redistribution to lysosomes in rat portal fibroblasts. Physiol Rep (2014) 0.75
The association between blood glucose levels and matrix-metalloproteinase-9 in early severe sepsis and septic shock. J Inflamm (Lond) (2016) 0.75
Evaluation of physiological risk factors, oxidant-antioxidant imbalance, proteolytic and genetic variations of matrix metalloproteinase-9 in patients with pressure ulcer. Sci Rep (2016) 0.75
Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK/MMP-9. Int J Ophthalmol (2016) 0.75
Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1. PLoS One (2017) 0.75
Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cells. Oncotarget (2016) 0.75
Investigation of MMP-2 and MMP-9 activities in canine sera with dilated cardiomyopathy. Iran J Vet Res (2015) 0.75
Microcurrent stimulation promotes reverse remodelling in cardiomyocytes. ESC Heart Fail (2016) 0.75
Pleiotropic Effects of Myocardial MMP-9 Inhibition to Prevent Ventricular Arrhythmia. Sci Rep (2016) 0.75
Role of Klotho in migration and proliferation of human dermal microvascular endothelial cells. Microvasc Res (2016) 0.75
Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus. Jpn J Ophthalmol (2017) 0.75
The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection. Sci Rep (2017) 0.75
Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer. PLoS One (2017) 0.75
Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Positively Modulates Matrix Metalloproteinase-9 Production in Alveolar Macrophages upon Toll-Like Receptor 7 Signaling and Influenza Virus Infection. Front Immunol (2017) 0.75
Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain. Heart Vessels (2017) 0.75
How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 14.05
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
The inflammatory response in myocardial infarction. Cardiovasc Res (2002) 7.92
Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (1994) 4.78
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem (2001) 3.48
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev (2005) 3.30
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem (2001) 3.03
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol (2001) 3.00
Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol (2009) 2.93
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation (2003) 2.89
Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol (2001) 2.66
Galectins: structure, function and therapeutic potential. Expert Rev Mol Med (2008) 2.61
Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation (1999) 2.56
Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol (2012) 2.47
Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol (1995) 2.46
Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest (2005) 2.44
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng (2004) 2.42
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res (2001) 2.38
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol (2007) 2.36
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem (1992) 2.34
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J (1991) 2.30
Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol (2001) 2.28
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation (1998) 2.11
The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol (1997) 2.07
Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res (2000) 2.05
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 1.95
Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest (2005) 1.94
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem (2003) 1.93
Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation (1995) 1.90
Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J (1997) 1.85
Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem (2001) 1.80
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med (2011) 1.74
Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun (2012) 1.70
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Nuclear factor kappa-B and the heart. J Am Coll Cardiol (2001) 1.68
Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res (1995) 1.63
Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry (1994) 1.63
Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res (2001) 1.62
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem (2004) 1.56
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol (2004) 1.49
Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation (2004) 1.48
Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein (1996) 1.45
S-nitrosylation: a potential new paradigm in signal transduction. Cardiovasc Res (2004) 1.44
Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med (2001) 1.43
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Patterns of myocardial fibrosis. J Mol Cell Cardiol (1989) 1.41
Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 1.39
Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol (2011) 1.37
Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension (2007) 1.36
Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation (2012) 1.36
Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res (1999) 1.34
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol (2005) 1.30
ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol (1999) 1.28
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev (2004) 1.27
Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem (1997) 1.26
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost (2009) 1.24
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem (1997) 1.19
Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol (2001) 1.17
The protein and lipid composition of arterial elastin and its relationship to lipid accumulation in the atherosclerotic plaque. J Clin Invest (1971) 1.15
The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem (2001) 1.15
Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res (2000) 1.14
A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci (2003) 1.14
Angiotensin II induces nuclear factor- kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol (2000) 1.14
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol (2002) 1.13
MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res (2000) 1.12
Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens (2011) 1.07
Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum (2008) 1.06
Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem (1998) 1.06
Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci (2001) 1.06
Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol (2006) 1.05
Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens (2007) 1.04
Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med (2003) 1.04
Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun (2007) 1.02
Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem (2007) 1.01
Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med (Maywood) (2004) 1.00
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytes. J Orthop Res (2006) 0.98
Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res (2007) 0.98
IL-1beta induces MMP-9 expression via a Ca2+-dependent CaMKII/JNK/c-JUN cascade in rat brain astrocytes. Glia (2009) 0.97
Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond) (2006) 0.96
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet (2011) 1.73
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res (2008) 1.47
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol (2005) 1.37
Extracellular matrix roles during cardiac repair. Life Sci (2010) 1.32
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res (2012) 1.25
The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 1.22
Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest (2011) 1.21
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms. Exp Gerontol (2007) 1.20
Hypertension: physiology and pathophysiology. Compr Physiol (2012) 1.18
Long-lived ames dwarf mice are resistant to chemical stressors. J Gerontol A Biol Sci Med Sci (2009) 1.18
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 1.13
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal (2013) 1.04
The left ventricle proteome differentiates middle-aged and old left ventricles in mice. J Proteome Res (2008) 1.04
Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics (2013) 1.01
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2013) 0.97
Mitral regurgitation in left ventricular noncompaction cardiomyopathy assessed by cardiac MRI. J Heart Valve Dis (2014) 0.97
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 0.96
In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res (2010) 0.95
Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther (2008) 0.94
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One (2012) 0.94
Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res (2012) 0.93
SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 0.90
Getting to the heart of the matter: age-related changes in diastolic heart function in the longest-lived rodent, the naked mole rat. J Gerontol A Biol Sci Med Sci (2012) 0.89
Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling post-myocardial infarction. BMC Genomics (2012) 0.89
Walking the oxidative stress tightrope: a perspective from the naked mole-rat, the longest-living rodent. Curr Pharm Des (2011) 0.88
Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol (2011) 0.88
Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal (2014) 0.88
Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol (2013) 0.87
Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J Tissue Eng Regen Med (2007) 0.86
Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl (2014) 0.86
Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine (2011) 0.86
Chronic diuretic therapy attenuates renal BOLD magnetic resonance response to an acute furosemide stimulus. J Cardiovasc Magn Reson (2014) 0.85
Mathematical modeling of left ventricular dimensional changes in mice during aging. BMC Syst Biol (2012) 0.85
Iridoids from the roots of Valeriana jatamansi and their neuroprotective effects. Fitoterapia (2011) 0.85
Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep (2014) 0.84
Is there a valid app for that? Validity of a free pedometer iPhone application. J Phys Act Health (2011) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Alterations of pulse pressure stimulate arterial wall matrix remodeling. J Biomech Eng (2009) 0.84
Proteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction. J Proteomics (2010) 0.84
Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets (2013) 0.84
Alterations in Pulse Pressure Affect Artery Function. Cell Mol Bioeng (2012) 0.84
Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl (2013) 0.83
Artery buckling stimulates cell proliferation and NF-κB signaling. Am J Physiol Heart Circ Physiol (2014) 0.83
Cardiac wound healing post-myocardial infarction: a novel method to target extracellular matrix remodeling in the left ventricle. Methods Mol Biol (2013) 0.83
Cardiac function of the naked mole-rat: ecophysiological responses to working underground. Am J Physiol Heart Circ Physiol (2013) 0.82
Bayesian parameter estimation for nonlinear modelling of biological pathways. BMC Syst Biol (2011) 0.82
ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol (2007) 0.82
Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat Anticancer Drug Discov (2007) 0.81
Roles of saturated vs. polyunsaturated fat in heart failure survival: not all fats are created equal. Cardiovasc Res (2011) 0.81
An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits P-glycoprotein and multidrug resistance-associate protein 1. Food Chem (2012) 0.81
DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity. Expert Opin Drug Discov (2012) 0.81
Sesquiterpenes from Vladimiria souliei and their inhibitory effects on NO production. Fitoterapia (2011) 0.81
Plasma fractionation enriches post-myocardial infarction samples prior to proteomics analysis. Int J Proteomics (2012) 0.80
Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension. Gend Med (2008) 0.80
Using systems biology approaches to understand cardiac inflammation and extracellular matrix remodeling in the setting of myocardial infarction. Wiley Interdiscip Rev Syst Biol Med (2014) 0.80
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail (2005) 0.80
Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here? J Mol Cell Cardiol (2009) 0.80
A conceptual cellular interaction model of left ventricular remodelling post-MI: dynamic network with exit-entry competition strategy. BMC Syst Biol (2010) 0.80
Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium. Congest Heart Fail (2013) 0.80
Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. Hypertens Res (2012) 0.80
A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich) (2013) 0.79
Obese and diabetic KKAy mice show increased mortality but improved cardiac function following myocardial infarction. Cardiovasc Pathol (2013) 0.79
[Study toxicity-attenuating effect and dose-toxicity relationship of rhubarb by processing based on correspondence analysis]. Zhongguo Zhong Yao Za Zhi (2009) 0.79
Is isolated systolic hypertension worse than combined systolic/diastolic hypertension? J Clin Hypertens (Greenwich) (2012) 0.78
Natural static magnetic field-induced apoptosis in liver cancer cell. Electromagn Biol Med (2013) 0.78
Thrombospondin-1: the good, the bad, and the complicated. Circ Res (2013) 0.78
Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. Methods Mol Biol (2013) 0.78
HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J (2008) 0.78
Titin phosphorylation: myocardial passive stiffness regulated by the intracellular giant. Circ Res (2009) 0.78
Cardiac assessment in pediatric mice: strain analysis as a diagnostic measurement. Echocardiography (2013) 0.78
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol Res (2010) 0.78
Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition. Cardiology (2015) 0.77
Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension (2012) 0.77
Crosstalk between cytotoxic T-lymphocyte associated antigen-4 and interleukin-12 in cytotoxic T-lymphocyte-mediated myocarditis: adding another link to the chain. Circ Res (2007) 0.77
New myrsinol diterpenes from Euphorbia prolifera and their inhibitory activities on LPS-induced NO production. Bioorg Med Chem Lett (2012) 0.77